{"name":"Quercis Pharma AG","slug":"quercis-pharma-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Kinisoquin™","genericName":"Kinisoquin™","slug":"kinisoquin","indication":"Treatment of type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Kinisoquin™","genericName":"Kinisoquin™","slug":"kinisoquin","phase":"phase_3","mechanism":"Kinisoquin is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQd2ZRdXFUTmd0OUdBY2phdF9IazUxUjVWSUpHTEJjNmkxVnNSakV6WWRBTXhyRngweFlITmF1aEJSbU9peXdlZ3lTQWRiZVdJc3owWUhxbDFIUmhZN0ViUGVYZGowYzlkanpScy1fOWMxbzdiak1fTl9rNHBnQlpuQTJvSFZnVXE1bkp2Zm9ZWV8wQQ?oc=5","date":"2025-10-21","type":"pipeline","source":"Yahoo Finance","summary":"Quercis Pharma and The Galien Foundation to Spotlight Sickle Cell Disease at the 2025 Patient Summit - Yahoo Finance","headline":"Quercis Pharma and The Galien Foundation to Spotlight Sickle Cell Disease at the 2025 Patient Summit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQWWJJbDUwenRKOFJBNXcteWZTQzA3ME95OVJBT1B1UmZiZWlZX2ZNMTFvTjFlZGxXRm1weU1MRHpzUVJWWmtMLXJRblk4YjZ6ZUpqQ0hwUUFEUG1NR0ZFZzF6MXEtaEtkR3hpMkM3X3VEVHd3Tmg4eE03Q2dvNzdNX1daa012R3VnZDdiVzFWdnVNUXJUcTB2a3hpaHp1UFhYVGJkakpUZXZQODdNc1RpSVR6bURSZ0doNDBRQzZMWGhWOWF3V1Q5NGpvU2dISWY1c1BBNUZUVzNJNm9VcUtVSG5CS0lOTV9MRlpPRjc1ZTJOd1ZDTXY4?oc=5","date":"2025-10-15","type":"pipeline","source":"GlobeNewswire","summary":"Quercis Pharma and Thomas Lines Nominated for Prestigious Prix Galien USA “Best Startup” Award - GlobeNewswire","headline":"Quercis Pharma and Thomas Lines Nominated for Prestigious Prix Galien USA “Best Startup” Award","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQendFRDN5aU1NQ0tpUUM1NjUzemlfN1FSaGg0a2pOSzh2ZE5PQWtmdnhTYWtiaVVXOXlhQm1RZWxjUl9oTEkxT3hKcWhlUDJ0Y3VlRm9Jc0hlUGhneWtTenp2MVRXWmhLSDhDYjJuU0w4X1hQbXJLb2VqTUR6bF9rN0ZUUW8?oc=5","date":"2021-12-13","type":"pipeline","source":"MassLive","summary":"Business Monday ETC: Dec. 13, 2021 - MassLive","headline":"Business Monday ETC: Dec. 13, 2021","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxQcnVIMUdyc0VsWXVINmwyYlM5cjB2SjctTXlMMFVZTkRzbXJjbnpxNFNMLU9tRlJCQ09IQ1pmTGFKWmNUbzd0dzZ3RVhseDZxamVCUy11OF90OTBzbktGTE5oNEVyUE1fd2hLRzZRaTNMYm80UmRjZ2FhMnhuRTY2cjhUTnhJZERLT21ST3FNREZxOFlKRWk3ZHlpbkxKTnlLZ005WmZUeFlWTHpOR3FkXzJ6eEpoendZR2N6ejdRUW5QQXlOMndHaW5rdExLeTltNk8yWWRRQWlSQWlxaGsxRERBcU50NGJWZzNxNjUtMmwzUWVOZ081TGZOZEpfX2dvRlE?oc=5","date":"2021-02-05","type":"trial","source":"Clinical Trials Arena","summary":"Quercis Pharma enlists Clinipace for Phase III trial of Kinisoquin - Clinical Trials Arena","headline":"Quercis Pharma enlists Clinipace for Phase III trial of Kinisoquin","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}